Therapeutic Advances in Musculoskeletal Disease

Papers
(The median citation count of Therapeutic Advances in Musculoskeletal Disease is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Successful treatment of severe COVID-19 pneumonia, a case series with simultaneous interleukin-1 and interleukin-6 blockade with 1-month follow-up118
Regenerative medicine for early osteoarthritis61
Comparison of the efficacy and risk of discontinuation between non-TNF-targeted treatment and a second TNF inhibitor in patients with rheumatoid arthritis after first TNF inhibitor failure34
Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study33
Actigraphy-derived physical activity levels and circadian rhythm parameters in patients with psoriatic arthritis: relationship with disease activity, mood, age and BMI27
Anti-sclerostin antibodies: a new frontier in fragility fractures treatment24
The impact of psoriatic arthritis on quality of life: a systematic review24
Poor health and functioning in patients with axial spondyloarthritis during the COVID-19 pandemic and lockdown: REUMAVID study (phase 1)23
To flare or not to flare: patients’ and rheumatologists’ perceptions on the on-flare retreatment strategy of rituximab in rheumatoid arthritis22
Early Osteoarthritis Questionnaire (EOAQ): a tool to assess knee osteoarthritis at initial stage22
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry20
Erratum to “Clinical effectiveness of symptomatic therapy compared with standard step-up care for the treatment of low-impact psoriatic oligoarthritis: the two-arm parallel group randomised POISE feas20
Mechanisms hypothesized for pain-relieving effects of exercise in fibromyalgia: a scoping review19
Is there wastage in the research resources for ankylosing spondylitis? An analysis of clinical trial discontinuation and nonpublication outcome18
Bone marrow edema in children: chronic nonbacterial osteomyelitis and its mimickers18
Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review17
Utilising a non-surgical intervention in the knee osteoarthritis care pathway: a 6-year retrospective audit on NHS patients17
Risk of ischaemic stroke among new users of glucosamine and chondroitin sulphate: a nested case–control study17
Systemic sclerosis associated interstitial lung disease: a survey of current practices in France16
MRI lesions in SpA: a comparison with noninflammatory back pain using propensity score adjustment method16
Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in ANA-positive Chinese patients16
Dispositional traits help explain individual differences in relationships between a radiographic knee osteoarthritis measure, pain, and physical function16
Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis15
The socioeconomic status of patients with ankylosing spondylitis and its association with the burden of the disease and permanent disability: a cross-sectional cluster analysis15
Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study14
Back pain treatment: a new perspective14
A novel infrapatellar approach of ultrasound-guided intra-articular injection of the knee from both lateral and medial side: a case series14
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance13
Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)13
Acute effects of exercise on pain symptoms, clinical inflammatory markers and inflammatory cytokines in people with rheumatoid arthritis: a systematic literature review13
Major adverse cardiovascular events or venous thromboembolism in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a nationwide, pop13
Fracture in clinical studies of tofacitinib in rheumatoid arthritis13
An oleuropein-based dietary supplement may improve joint functional capacity in older people with high knee joint pain: findings from a multicentre-RCT and post hoc analysis13
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib13
Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus12
Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice12
An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis12
Counting the costs: a nationwide study on healthcare use following an adalimumab biosimilar switch in >1300 inflammatory arthritis patients12
The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease12
Comparable long-term retention rates and effects on bone mineral density of denosumab treatment in patients with osteoporosis with or without autoimmune inflammatory rheumatic diseases: real-life data12
Retraction notice11
Risk factors associated with the occurrence of total knee arthroplasty in patients with knee osteoarthritis: a nested case–control study11
Potential complementary and/or synergistic effects of curcumin and boswellic acids for management of osteoarthritis11
Thanks to Reviewers10
Early-stage hypertension defined by the 2017 ACC/AHA blood pressure guideline carries excessive cardiovascular risk in axial spondyloarthritis patients10
Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review10
Predictive model to identify multiple failure to biological therapy in patients with rheumatoid arthritis10
Infections in psoriatic arthritis: association with treatment10
SCORE2 is superior to SCORE in predicting the presence of carotid plaques and intima-media thickness in rheumatoid arthritis patients: a cross-sectional study using carotid ultrasound10
Incidence rate of and risk factors for glomerulonephritis in patients with axial spondyloarthritis: a nationwide population-based study9
Switching from rituximab originator to GP2013 or CT-P10 biosimilars in autoimmune rheumatic diseases: drug retention rate and safety data from a multicentric retrospective cohort9
Imaging in psoriatic arthritis: established methods and emerging techniques9
Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic 9
The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P29
Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol9
New insights on multigenic autoinflammatory diseases9
The protocol of a clinical effectiveness trial comparing standard step-up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthri9
New insights in lower limb reconstruction strategies8
Efficacy and safety of biologic agents for the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials8
Precision medicine using molecular-target drugs in psoriatic arthritis8
Precision medicine in axial spondyloarthritis: current opportunities and future perspectives8
Big data analyses and individual health profiling in the arena of rheumatic and musculoskeletal diseases (RMDs)8
SCORE2 versus SCORE in patients with systemic lupus erythematosus7
Pregnancy in juvenile idiopathic arthritis: maternal and foetal outcome, and impact on disease activity7
Circulating microRNAs differentiate fast-progressing from slow-progressing and non-progressing knee osteoarthritis in the Osteoarthritis Initiative cohort7
Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy7
The analysis of the pulmonary domain involvement in Sjögren’s disease7
Comparison of clinical efficiency between intra-articular injection of platelet-rich plasma and hyaluronic acid for osteoarthritis: a meta-analysis of randomized controlled trials7
A glance into the future of gout7
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge6
Primary non-response in inflammatory arthritis treated with biologics and targeted therapies in daily clinical practice6
A broad look into the future of rheumatoid arthritis6
The interplay between dysregulated metabolites and signaling pathway alterations involved in osteoarthritis: a systematic review6
Artificial intelligence in rheumatology: status quo and quo vadis—results of a national survey among German rheumatologists6
The signature of the gut microbiota associated with psoriatic arthritis revealed by metagenomics6
Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients6
Intra-articular placebo effect in the treatment of knee osteoarthritis: a survey of the current clinical evidence6
Risk factors and prognosis of depression in Takayasu arteritis patients5
Effects of adipose-derived mesenchymal stem cell conditioned medium on human tenocytes exposed to high glucose5
A glance into the future of myositis therapy5
Characterization of missing data patterns and mechanisms in longitudinal composite outcome trial in rheumatoid arthritis5
The incidence of vasculitides in Israel from 2007 to 2021 and during the COVID-19 pandemic5
Calcineurin inhibitors in systemic sclerosis – a systematic literature review5
Long-term efficacy and safety of neridronate treatment in patients with complex regional pain syndrome type 1: a pre-specified, open-label, extension study5
Mapping two decades of research in rheumatology-specific journals: a topic modeling analysis with BERTopic5
Efficacy and safety of abatacept in patients with rheumatoid arthritis with previous malignancy4
Medication holidays in osteoporosis: evidence-based recommendations from the Italian guidelines on ‘Diagnosis, risk stratification, and continuity of care of fragility fractures’ based on a systematic4
Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exp4
Osteosarcopenia and Long-COVID: a dangerous combination4
Effectiveness and safety of immunoadsorption as a rescue treatment of inflammatory myopathies: report of three cases and literature review4
The challenge of pharmacotherapy for musculoskeletal pain: an overview of unmet needs4
Reduced bone mineral density in patients with idiopathic inflammatory myopathies: a case-control study4
Health disparities in rheumatoid arthritis4
Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies4
Uveitis in peripheral spondyloarthritis patients: an ancillary analysis of the ASAS-PerSpA study4
Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry4
A broad look into the future of systemic sclerosis4
Impact of daily physical therapy over 2 weeks on spinal mobility including objective electronic measurements and function in patients with axial spondyloarthritis4
Cost-effectiveness of specialised manual therapy versus orthopaedic care for musculoskeletal disorders: long-term follow-up and health economic model4
Latest insights in disease-modifying osteoarthritis drugs development4
Racial and ethnic differences in the pharmacologic management of osteoarthritis: rapid systematic review3
Frequency and anatomic distribution of magnetic resonance imaging lesions in the sacroiliac joints of spondyloarthritis and non-spondyloarthritis patients3
Wearable transcutaneous electrical nerve stimulation (actiTENS®) is effective and safe for the treatment of knee osteoarthritis pain: a randomized controlled trial versus weak opioids3
Relationship between onset of psoriasis and spondyloarthritis symptoms with clinical phenotype and diagnosis: data from REGISPONSER registry3
SARS-CoV-2 vaccination willingness and predictors in patients with chronic inflammatory rheumatic diseases (CIRD) and without CIRD3
Plasma calprotectin as a biomarker of ultrasound synovitis in rheumatoid arthritis patients receiving IL-6 antagonists or JAK inhibitors3
Predicting osteoarthritis in adults using statistical data mining and machine learning3
Comparative efficacy and safety of mizoribine and mycophenolate mofetil for treating systemic lupus erythematosus: a retrospective cohort study3
What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes?3
Neuro-PIMS-TS: a single case report and review of the literature3
Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials3
Factors associated with radiographic progression in rheumatoid arthritis starting biological diseases modifying anti-rheumatic drugs (bDMARDs)3
Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes3
Oral enzyme combination with bromelain, trypsin and the flavonoid rutoside reduces systemic inflammation and pain when used pre- and post-operatively in elective total hip replacement: a randomized ex3
0.085747957229614